Stephen Yoo
Amministratore Delegato presso Anjarium Biosciences AG
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Curran Simpson | M | 62 | 9 anni | |
David Stump | M | 74 | 9 anni | |
Argeris Karabelas | M | 71 | 9 anni | |
Daniel Tassé | M | 64 | 8 anni | |
Ram Palanki | M | 48 | 6 anni | |
Alexandra Glucksmann | M | 65 | 6 anni | |
Shiva G. Fritsch | F | - | 7 anni | |
Patrick Christmas | M | 53 | 8 anni | |
Douglas Fambrough | M | 55 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 anni |
Dina Chaya | M | 52 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 3 anni |
Olivier Danos | M | 66 | 7 anni | |
Bali Muralidhar | M | 44 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | - |
Jerome W. Jackson | M | - | 9 anni | |
Gaurav D. Shah | M | 49 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 anni |
Samantha Vieira | F | - |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Luke Beshar | M | 65 | 6 anni | |
Edgar Engleman | M | 78 | 1 anni | |
Camille Samuels | F | 52 | 1 anni | |
Daniel Abdun-Nabi | M | 69 | 6 anni | |
Sara Garon Berl | F | - | 8 anni | |
Benjamin Auspitz | M | 51 | - | |
Michael C. Gelman | M | - | - | |
John Daniel Kiser | M | - | - | |
Faraz Ali | M | 51 | 2 anni | |
Lynne McGrath | M | 69 | 3 anni | |
Rickey Reinhardt | M | - | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 21 | 80.77% |
Svizzera | 5 | 19.23% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Stephen Yoo
- Contatti personali